NCT03042793View on ClinicalTrials.gov

Vaccination With PD-L1 Peptide Against Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

May 14, 2020

Study Completion Date

May 14, 2020

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

PD-L1 peptide vaccine

PD-L1 peptide given subcutaneously with Montanide ISA-51

Trial Locations (1)

2730

Department of Hematology, Universityhospital Herlev and Gentofte, Herlev

All Listed Sponsors
lead

Lene Meldgaard Knudsen

OTHER

NCT03042793 - Vaccination With PD-L1 Peptide Against Multiple Myeloma | Biotech Hunter | Biotech Hunter